LifeMine Therapeutics, a Boston, MA-based drug discovery company, closed a $55m Series A financing.
The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite Capital, GV (formerly Google Ventures), Arch Ventures, Boyu Capital, Blue Pool Capital, Merck Ventures, and Alexandria Venture Investments.
Led by Gregory Verdine, co-founder, president and chief executive officer, LifeMine has built a drug discovery platform that can rapidly develop new drugs for chronic diseases from eukaryotic microbes by combining genomics with artificial intelligence and synthetic biology.
In association with the financing, the company has appointed Edward Hu, founding partner, WuXi Healthcare Ventures; James Tananbaum, founder and CEO, Foresite Capital; Krishna Yeshwant, general partner, GV; Yanling Cao, managing director, Boyu Capital; and Rick Klausner, founder and director, Juno Therapeutics, GRAIL, and Mindstrong, to its board of directors.
Klausner will Chair the board while Verdine (who founded LifeMine along with WeiQing Zhou, entrepreneur-in-residence at WuXi Healthcare Ventures and chief operating officer at LifeMine, and Hingge Hsu, veteran venture capitalist and a senior adviser to WuXi Healthcare Ventures) also serves on LifeMine’s board.
The company has additional offices in New York.